^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mecbotamab vedotin (BA3011)

    i
    Other names: Mec-V, BA3011, BA-3011, BA 3011, CAB-AXL-ADC, CAB-Axl antibody-drug conjugate, HTBA3011, AXL-ADC
    Company:
    BioAtla
    Drug class:
    Microtubule inhibitor, AXL-targeted antibody-drug conjugate
    Related drugs:
    2ms
    CRI-CCTG-0003/IND.240: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    Imfinzi (durvalumab) • Loqtorzi (toripalimab-tpzi) • mecbotamab vedotin (BA3011) • ENB003
    2ms
    BA3011-002: CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC (clinicaltrials.gov)
    P2, N=85, Completed, BioAtla, Inc. | Active, not recruiting --> Completed | N=240 --> 85
    Trial completion • Enrollment change
    |
    mecbotamab vedotin (BA3011)
    2ms
    BA3011-001: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma (clinicaltrials.gov)
    P1/2, N=245, Completed, BioAtla, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jan 2025
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • mecbotamab vedotin (BA3011)
    6ms
    BA3011-001: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma (clinicaltrials.gov)
    P1/2, N=300, Active, not recruiting, BioAtla, Inc. | Trial completion date: Jan 2025 --> Jun 2025
    Trial completion date
    |
    Opdivo (nivolumab) • mecbotamab vedotin (BA3011)
    6ms
    Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate. (PubMed, Antib Ther)
    Furthermore, in nonhuman primates, mecbotamab vedotin demonstrated excellent tolerability at doses of up to 5 mg/kg and maintained linker-payload stability in vivo. These findings indicate that mecbotamab vedotin has the potential to be a robust and less toxic therapeutic agent, offering promise as a treatment for patients with AXL-positive cancers.
    Preclinical • Journal
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    AXL positive
    |
    mecbotamab vedotin (BA3011)
    11ms
    BA3011-001: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma (clinicaltrials.gov)
    P1/2, N=300, Active, not recruiting, BioAtla, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • mecbotamab vedotin (BA3011)
    11ms
    CRI-CCTG-0003/IND.240: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • Loqtorzi (toripalimab-tpzi) • mecbotamab vedotin (BA3011) • ENB003
    1year
    BA3011-002: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC (clinicaltrials.gov)
    P2, N=240, Active, not recruiting, BioAtla, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    mecbotamab vedotin (BA3011)
    over1year
    CRI-CCTG-0003/IND.240: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Canadian Cancer Trials Group | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial primary completion date
    |
    Imfinzi (durvalumab) • mecbotamab vedotin (BA3011)
    over1year
    Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations. (PubMed, Drugs R D)
    So far, the antibody-drug conjugates have struggled from efficacy problems, with modest effects at best, leading many to be discontinued for melanoma. At the same time, conjugates such as AMT-253, targeting melanoma cell adhesion molecule, and mecbotamab vedotin  targeting AXL receptor tyrosine kinase, are among the most exciting for melanoma treatment in the future.
    PK/PD data • Review • Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • MCAM (Melanoma Cell Adhesion Molecule)
    |
    mecbotamab vedotin (BA3011) • AMT-253
    over1year
    BA3011-001: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma (clinicaltrials.gov)
    P1/2, N=300, Recruiting, BioAtla, Inc. | N=120 --> 300
    Enrollment change • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • mecbotamab vedotin (BA3011)